Hi Timomo. That was the original number analysts estimated for Trofinetide, Neuren’s FDA approved drug. As it turns out the actual drug cost will be $375k per patient per annum. Hence the daily re-rate upwards for Neuren.
Pricing for BOT will be similar to Qbrexa or at a slight premium to it. This has been stated by Howe in the latest investor video.
Ann: Investor Presentation, page-33
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
-0.005(1.79%) |
Mkt cap ! $433.1M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 29.0¢ | 27.0¢ | $1.828M | 6.618M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 1238357 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 31084 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
27.5¢ |
Change
-0.005 ( 3.51 %) |
||||
| Open | High | Low | Volume | ||
| 28.5¢ | 29.0¢ | 27.0¢ | 3100791 | ||
| Last updated 15.59pm 10/05/2024 ? | |||||
| BOT (ASX) Chart |